Top 10 healthcare companies by revenues | 2026 Rank Company Q1 H1 9M 2026 revenues 1 United Health Group $111.7 $223.7 2 CVS Health $100.4 3 Cigna Group $68.5 4 Centene $49.9 5 Elevance Health $49.5 6 Humana $39.6 7 Kaiser Permanente $34.6 8 HCA Healthcare $19.1 9 HCSC $16.6 10 Molina Healthcare $10.8 Top Healthcare Companies by Revenues | 2026 United Health Group Q1 REVENUES: UnitedHealth Group reported first-quarter 2026 revenues of $111.7 billion, representing a 2% increa

On July 16, 2026, the Centers for Medicare & Medicaid Services (CMS) issued a new draft guidance that fills in critical operational details for the Inflation Reduction Act’s drug price negotiation program. The document explains how pharmaceutical manufacturers will be expected to implement Medicare’s negotiated prices when they go live in 2028, with specific expectations for both pharmacy-dispensed and physician-administered therapies. For life sciences companies, this guidan

The Centers for Medicare & Medicaid Services (CMS) has unveiled a comprehensive, three-pillar strategy aimed at fundamentally restructuring Original Medicare (OM) by transitioning away from traditional, fragmented fee-for-service payment models. The new framework seeks to optimize spending efficiency, expand patient-centric decision-making, and strengthen provider accountability within the Medicare Shared Savings Program. This initiative reflects the agency’s intensified focu

Key Regulatory Proposals Aetna, a CVS Health company, has released the results of its second quarterly Provider Survey, highlighting a notable shift in the relationship between healthcare payers and providers. According to the data, the average provider trust score for payers has increased to 6.1, up from 5.4 in the first quarter of the year. Approximately 38% of survey participants now rate their payer partners an 8 or higher on a 10-point scale. Operational improvements app

The Centers for Medicare & Medicaid Services (CMS) has introduced a broad regulatory proposal aimed at restructuring Medicare physician payments and accelerating the transition toward value-based care. The initiative centers on four strategic objectives: Broadening participation in accountable care models Refining payment methodologies Streamlining administrative operations Prioritizing proactive preventative medicine over traditional reactive healthcare delivery Key Regulato

A major transition is underway in the U.S. pharmacy benefit sector as corporate employers increasingly abandon traditional rebate-based structures in favor of transparent, fee-only models. Recent data from the Penta Group indicates that nearly 90% of U.S. employers are now actively seeking pharmacy benefit management (PBM) agreements that bypass legacy rebate systems to ensure that negotiated drug savings are passed directly to plan members. Also read: CVS Pharmacy Joins Medi

Optum Financial has completed the acquisition of Alegeus Technologies, adding a major benefits administration platform to its consumer finance business. Alegeus runs software that powers consumer‑directed healthcare accounts such as health savings accounts, flexible spending accounts, health reimbursement arrangements and COBRA coverage for millions of members. The deal fits within UnitedHealth Group’s broader push to deepen its presence in healthcare payments and benefit f

CVS Pharmacy is expanding its support for people using GLP-1 medicines for weight management and metabolic health, as demand for these drugs continues to rise in the United States. The company is integrating new access, clinical, and product initiatives across more than 9,000 CVS Pharmacy locations and its MinuteClinic virtual care platform, which serves most states. Also read: Top 10 Pharma Companies by Revenue in 2025 The approach brings together three elements that often l

Eli Lilly is preparing to launch a new access route intended to help some Medicare beneficiaries obtain GLP-1-based obesity treatments. The Medicare GLP-1 Bridge program marks a notable change in how weight‑management medicines may be covered for older adults and other Part D enrollees. What is the Medicare GLP-1 Bridge program? The Medicare GLP-1 Bridge program is a time-limited initiative created by Eli Lilly to give a subset of Medicare Part D members lower-cost access t

Sanofi has secured US regulatory clearance for Tzield as a treatment aimed at modifying disease progression in children recently diagnosed with stage 3 type 1 diabetes. The authorization marks the first time a therapy has been approved in this setting to help preserve the body’s own insulin production. The US Food and Drug Administration granted accelerated approval for Tzield for use in patients aged 8 to 17 years who have been newly diagnosed with stage 3 type 1 diabetes.

CVS Caremark is repositioning its GLP-1 weight management strategy to focus on both affordability and broader access, instead of simply expanding coverage as a routine update. The key operational moves are the reintroduction of Zepbound (tirzepatide) as a preferred option on its commercial formularies from October 1, 2026, and the removal of the new-to-market block on Foundayo (orforglipron), an oral GLP-1 therapy, effective June 1, 2026. These decisions indicate that CVS Car

The Council of Economic Advisers has published a detailed analysis of the Trump Administration’s Most-Favored-Nation (MFN) drug pricing framework, outlining how the policy could deliver substantial savings to U.S. patients and public programs while rebalancing who pays for pharmaceutical innovation worldwide. The framework combines voluntary agreements with major manufacturers, new reference pricing rules, and targeted reforms to Medicaid, direct‑to‑consumer markets, and Medi

UnitedHealthcare is rolling back prior authorization requirements for a substantial share of its book of business, in a move the company says is aimed at cutting red tape and speeding access to care. The insurer plans to drop prior authorization for 30% of services that previously needed approval and has set a goal to remove an additional 30% of remaining authorizations by the end of 2026, covering categories such as select outpatient surgeries, echocardiograms, outpatient th

The American Hospital Association (AHA) has called on the Health Resources and Services Administration (HRSA) to stop a new Eli Lilly and Company policy that would expand claims‑data reporting requirements for 340B hospitals, warning that the change is unlawful, unworkable, and threatens patient access to discounted medicines. Also read: Top 10 pharmaceutical companies by revenues On January 15, 2026, Lilly notified 340B covered entities that, effective February 1, all enti

CVS Health has laid out a broad strategy to simplify how Americans use health insurance while tackling the rising cost of care and medicines. The company stated that it is focused on easing administrative burdens for clinicians, shifting payments toward value, and expanding the use of lower‑cost treatment options. Making utilization management less burdensome Aetna, the health insurance arm of CVS Health, reports that it now applies prior authorization requirements to fewer m

Six of the world’s largest drugmakers – GSK, Novartis, Merck, Gilead, Bristol Myers Squibb and Amgen – have struck three‑year agreements with the Trump administration to cut US drug prices, expand direct‑to‑patient access and commit tens of billions of dollars to American R&D and manufacturing. Taken together, these deals form the core of a new TrumpRx and “Most Favored Nation” framework that trades tariff relief and policy predictability for visible price cuts on high‑impact

FDA Greenlights Breyanzi: Pioneering CAR T-Cell Therapy for Marginal Zone Lymphoma The U.S. Food and Drug Administration has approved Breyanzi (lisocabtagene maraleucel) for adults battling relapsed or refractory marginal zone lymphoma (MZL) after at least two prior lines of systemic therapy. This groundbreaking decision positions Breyanzi as the first CAR T-cell therapy approved in the U.S. for this challenging rare B-cell malignancy, offering new hope to patients with limit

Dual Special Needs Plans (D-SNPs) are Medicare Advantage plans designed for individuals eligible for both Medicare and Medicaid, offering coordinated coverage that integrates medical, prescription, and supplemental benefits to address complex needs. These plans cover Medicare Parts A, B, and often D alongside Medicaid services like long-term care and behavioral health support, typically with low or no cost-sharing. UnderstandingD-SNPs for Dual Eligibles D-SNPs target "dual el

Eli Lilly has cut out‑of‑pocket prices for its obesity drug Zepbound in the United States, lowering the monthly cost of single‑dose vials for patients who pay cash through its LillyDirect platform in an effort to broaden access to tirzepatide.​ New Zepbound vial pricing and regular prices Under the updated Zepbound Self‑Pay Journey Program on LillyDirect, patients with a valid prescription can now obtain the starter 2.5 mg vial for about 299 dollars per month, down from rou

CMS has introduced the ACCESS (Advancing Chronic Care with Effective, Scalable Solutions) Model, a new 10‑year voluntary payment model in Original Medicare designed to expand technology‑supported care for people living with chronic diseases. The first performance period begins July 1, 2026, with applications due by April 1, 2026; applications submitted after that date will be considered for a January 1, 2027 start.​ What is the ACCESS Model? The ACCESS Model tests an outcom

The Centers for Medicare & Medicaid Services (CMS) has proposed new policies for Medicare Advantage (MA) and Medicare Part D plans, aiming to improve quality, boost access, and support innovative benefit designs. The 2027 draft rule details significant changes to the Star Ratings system and invites public comments on how to further modernize Medicare Advantage for both beneficiaries and taxpayers. Also read: Top 10 pharmaceutical companies by revenues Under these proposed u

Merck announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa) in combination with Padcev (enfortumab vedotin) for the perioperative treatment of adults with muscle‑invasive bladder cancer (MIBC) who are ineligible for cisplatin‑based chemotherapy. The regimen includes neoadjuvant therapy before surgery followed by adjuvant treatment after cystectomy. These approvals mark the

CVS Pharmacy Launches Transparent CostVantage Model for Prescription Pricing In a bold move to reshape the retail pharmacy landscape, CVS...

The Institute for Clinical and Economic Review (ICER) recently conducted an assessment of insurance coverage policies for 11 prescription...

CMS Unveils Further Instructions on Initiative Allowing Medicare Beneficiaries to Manage Prescription Drug Expenses via Monthly Payments....

November 09, 2023 Optum Rx Implements Initiatives to Reduce Insulin Expenses Commencing on January 1, 2024, Optum Rx is undertaking...

Cigna Healthcare has unveiled significant enhancements to its service by eliminating the requirement for prior authorization (or...

The Institute for Clinical and Economic Review (ICER) has published its definitive evidence report on gene therapies for Sickle Cell...

CVS Health has unveiled an initiative by launching Cordavis, a wholly-owned subsidiary, to spearhead introducing high-quality biosimilar...